ClinConnect ClinConnect Logo
Search / Trial NCT05664178

Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology

Launched by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE · Dec 16, 2022

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Gastrointestinal Cancer Remote Resistance Exercise Gi Cancer Stage Iii Gi Cancer Stage Iv Tele Resistance Training

ClinConnect Summary

This clinical trial, called "Remote Resistance Exercise Powering Survivors," is looking at how a special exercise program delivered online can help people undergoing chemotherapy for advanced upper gastrointestinal (GI) cancer. The goal is to see if this remote exercise training can improve strength and overall well-being for those fighting this type of cancer.

To participate in this study, individuals must be at least 18 years old and have a confirmed diagnosis of advanced upper GI cancer (stages III or IV). They should also be able to read and speak English and be planning to return to Moffitt Cancer Center for further treatment. While the trial is open to anyone meeting these criteria, it excludes those who already engage in regular resistance training, have certain health issues that could affect their ability to exercise safely, or experience significant pain. Participants can expect to take part in guided exercise sessions online, which will be tailored to their needs and abilities during their treatment journey.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 18 years
  • Biopsy-proven upper GI cancer, stage III-IV
  • ECOG performance status 0-1
  • Treatment plan of chemotherapy with planned return to Moffitt Cancer Center for restaging
  • Able to read and speak English fluently
  • Capable of providing informed consent
  • Exclusion Criteria:
  • Regular engagement in RT (2x/week targeting all major muscle groups)
  • Screen failure for exercise safety based on Physical Activity Readiness Questionnaire (PAR-Q) and Patient-Reported Measurement Information System (PROMIS) screening questions
  • Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease (New York Heart Association functional class III or IV).
  • Recent fracture or acute musculoskeletal injury that precludes ability to participate in RT
  • Numeric pain rating scale of ≥ 7 out of 10
  • Myopathic or rheumatologic disease that impacts physical function

About H. Lee Moffitt Cancer Center And Research Institute

H. Lee Moffitt Cancer Center and Research Institute is a leading institution dedicated to cancer research, treatment, and education, recognized for its commitment to advancing cancer care through innovative clinical trials and groundbreaking research. As a National Cancer Institute-designated Comprehensive Cancer Center, Moffitt integrates cutting-edge science with patient-centered care, offering a multidisciplinary approach to cancer treatment. The center is at the forefront of developing novel therapies and improving outcomes for patients, emphasizing collaboration between researchers and clinicians to translate scientific discoveries into effective treatments. Through its extensive clinical trial programs, Moffitt aims to enhance the understanding of cancer biology and provide patients with access to the latest therapies and interventions.

Locations

Tampa, Florida, United States

Patients applied

0 patients applied

Trial Officials

Nathan Parker, PhD, MPH

Principal Investigator

Moffitt Cancer Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials